Amedeo's Top 20

Amedeo Smart

Independent Medical Education

29 August 2022

Multidisciplinary Journal Club

  1. Mollenhauer B, von Arnim CAF.
    Toward preventing Parkinson's disease.
    Science 2022;377:818-819.

  1. Roos I, Malpas C, Leray E, Casey R, et al.
    Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis.
    Neurology 2022.

  2. Kirchgesner J, Desai RJ, Schneeweiss MC, Beaugerie L, et al.
    Decreased risk of treatment failure with vedolizumab and thiopurines combined compared with vedolizumab monotherapy in Crohn's disease.
    Gut 2022;71:1781-1789.

  3. Iaffaldano P, Lucisano G, Guerra T, Patti F, et al.
    Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS Register.
    Mult Scler 2022.

  4. Cohen-Mekelburg S, Van T, Wallace B, Berinstein J, et al.
    The association between non-steroidal anti-inflammatory drug use and inflammatory bowel disease exacerbations: a true association or residual bias?
    Am J Gastroenterol 2022.

  1. Fairbrass KM, Lovatt J, Barberio B, Yuan Y, et al.
    Bidirectional brain-gut axis effects influence mood and prognosis in IBD: a systematic review and meta-analysis.
    Gut 2022;71:1773-1780.

  2. Kedia S, Virmani S, K Vuyyuru S, Kumar P, et al.
    Faecal microbiota transplantation with anti-inflammatory diet (FMT-AID) followed by anti-inflammatory diet alone is effective in inducing and maintaining remission over 1 year in mild to moderate ulcerative colitis: a randomised controlled
    Gut 2022.

  3. Jongs N, Chertow G, Greene T, McMurray J, et al.
    Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with Chronic Kidney Disease.
    J Am Soc Nephrol 2022.

  4. Chen B, Zhong J, Li X, Pan F, et al.
    Efficacy and Safety of Ivarmacitinib in Patients with Moderate-to-Severe, Active, Ulcerative Colitis: A Phase II Study.
    Gastroenterology 2022.

  5. Sandoval Y, Apple FS, Mahler SA, Body R, et al.
    High-Sensitivity Cardiac Troponin and the 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guidelines for the Evaluation and Diagnosis of Acute Chest Pain.
    Circulation 2022;146:569-581.

  1. Docherty KF, Welsh P, Verma S, De Boer RA, et al.
    Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF.
    Circulation 2022.

  2. Grote A, Heiland DH, Taube J, Helmstaedter C, et al.
    'Hippocampal innate inflammatory gliosis only' in pharmacoresistant temporal lobe epilepsy.
    Brain 2022.

  3. Prasannakumar A, Kumar V, Rao NP.
    Trust and psychosis: a systematic review and meta-analysis.
    Psychol Med 2022.

  4. Liu Z, Grant J, Simpson SP, Khattak A, et al.
    Driving Ability Evaluation and Rehabilitation for People With Alzheimer's Disease and Related Dementias.
    Alzheimer Dis Assoc Disord 2022.

  5. Jurgens CY, Lee CS, Aycock DM, Masterson Creber R, et al.
    State of the Science: The Relevance of Symptoms in Cardiovascular Disease and Research: A Scientific Statement From the American Heart Association.
    Circulation 2022.

  1. Bal C, Satapathy S, Tupalli A, Ballal S, et al.
    Propensity Score Matched Outcome Analysis of Lobar Ablation versus Completion Thyroidectomy in Low-risk Differentiated Thyroid Cancer Patients: Median Follow-up of 11 Years.
    Thyroid 2022.

  2. Rolfo C, Malapelle U, Russo A.
    Expanding the Full Potential of Liquid Biopsies for Lung Cancer Patients.
    Cancer Res 2022;82:2826-2828.

  3. Safarpour D, Brumbach BH, Arena M, Quinn J, et al.
    Gastrointestinal Motility and Response to Levodopa in Parkinson's Disease: A Proof-of-Concept Study.
    Mov Disord 2022.

  4. Godet T, De Jong A, Garin C, Guerin R, et al.
    Impact of Macintosh blade size on endotracheal intubation success in intensive care units: a retrospective multicenter observational MacSize-ICU study.
    Intensive Care Med 2022.

  5. Zeng E, He W, Sjolander A, Bergqvist J, et al.
    Determinants and effectiveness of extending the duration of adjuvant hormone therapy beyond 5 years in breast cancer patients.
    Cancer Res 2022.


more..

Privacy Policy